NASDAQ:JANX

Janux Therapeutics Q4 2024 Earnings Results & Report

Janux Therapeutics logo
$10.31 -0.40 (-3.73%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$10.40 +0.09 (+0.83%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Janux Therapeutics beat analyst earnings expectations in its Q4 2024 results, released February 27, 2025. The company reported EPS of -$0.36 versus the -$0.49 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call
4:00 PM ET

Janux Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
-$0.49
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Janux Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Janux Therapeutics Q4 2024 Earnings FAQ

Janux Therapeutics (NASDAQ:JANX) reported earnings of -$0.36 per share for Q4 2024, beating the consensus estimate of -$0.49. The report was announced on Thursday, February 27, 2025.

Janux Therapeutics Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. The company’s research focuses on engaging a patient’s T cells to recognize and attack tumors.

Janux’s proprietary platforms are designed to keep certain immune therapies inactive until they reach the tumor environment, with the goal of limiting activity in healthy tissues. Its clinical-stage programs include candidates directed at targets such as PSMA and EGFR, and its broader pipeline includes additional investigational cancer therapies.

Based in San Diego, California, Janux was founded in 2017. The company is led by co-founder David Campbell, Ph.D., who serves as president and chief executive officer.

View Janux Therapeutics Profile